| 证券代码 | EIDX.O |
| 证券名称 | Eidos Therapeutics Inc |
| 证券类型 | 美股 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | 主板 |
| 发行方式 | 公开发售 |
| 首发上市日 | 2018-06-20 |
| 首发价格(元) | 17 USD |
| 首发数量(股) | 6250000 |
| 首发募资额(元) | 106,250,000.00 USD |
| 首发主承销商 | J.P. Morgan Securities LLC,Merrill Lynch, Pierce, Fenner & Smith |
| 货币单位 | USD |
| 公司名称 | Eidos Therapeutics, Inc. |
| 注册地址 | 美国特拉华州 |
| 办公地址 | 101 Montgomery Street, Suite 2550, San Francisco, California, USA |
| 成立日期 | 2013-08-06 |
| 董事会主席 | - |
| 公司属地 | United States 美国 |
| 公司网址 | www.eidostx.com |
| 电话 | +1 (415) 887-1471 |
| 传真 | - |
| 公司简介 | Eidos Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin, or TTR, amyloidosis, or ATTR. It seeks to treat this well-defined family of diseases by targeting them at their collective source by stabilizing TTR. TTR is a protein that occurs naturally in the form of a tetramer (a molecular structure consisting of four identical subunits, or monomers) and performs multiple beneficial roles, including the transport of essential hormones and vitamins. Over 25 years of research have shown that ATTR is uniformly driven by destabilization of the TTR tetramer, stemming from either specific gene mutations or aging. TTR destabilization drives an irreversible dissociation of the tetramer into monomers, which subsequently aggregate and deposit predominantly in the heart and peripheral nervous system, leading to organ damage, loss of organ function, and eventual death if left untreated. There are currently no therapies approved by the U.S. Food and Drug Administration, or FDA, for the treatment of ATTR. It is building upon its significant mechanistic understanding of ATTR to develop a potentially disease-modifying treatment for this family of diseases. |